Skip to main content

Table 1 Characteristics of the CARLA study population

From: Advanced glycation end products and their ratio to soluble receptor are associated with limitations in physical functioning only in women: results from the CARLA cohort

 

Men (n = 967)

Women (n = 812)

Age, mean ± SD (years)

65 ± 10.23

64 ± 9.94

<  65 years, N (%)

487 (50.36)

455 (56.03)

> = 65 years, N (%)

480 (49.64)

357 (43.97)

BMI, mean ± SD, (kg/m2)

28.15 ± 4.08

28.54 ± 5.36

Smoker, N, yes (%)

225 (23.27)

119 (14.66)

Food indexa, mean ± SD

14.52 ± 3.20

16.44 ± 3.16

Diabetes mellitus, N (%)

154 (15.93)

120 (14.78)

Cardiovascular disease, N (%)

153 (15.82)

48 (5.91)

Osteoporosis, N (%)

64 (6.62)

142 (17.49)

Creatinine clearance, median (P25/P75) (ml/min)

97.22 (76.61/119.41)

88.95 (71.76/109.86)

AGE-levels, median (P25/P75) (relative units)

12,289 (9548/14796)

11,385 (8574/13712)

sRAGE-levels, median (P25/P75) (pg/ml)

827.62 (604.41/1107.88)

964.49 (706.93/1279.58)

AGE/sRAGE, median (P25/P75)

14.46 (10.01/21.09)

11.38 (8.19/16.37)

Limitations in moderate activities, N (%)

 Severe limitation

61 (6.31)

78 (9.61)

 Minor limitation

246 (25.44)

305 (37.56)

 No limitation

660 (68.25)

429 (52.83)

Limitations in climbing stairs, N (%)

 Severe limitation

69 (7.14)

90 (11.08)

 Minor limitation

361 (37.33)

385 (47.41)

 No limitation

537 (55.53)

337 (41.50)

  1. Note. CRP High sensitive C-reactive protein, BMI Body Mass Index, AGEs Advanced glycation end products, sRAGE Soluble receptor of AGEs, SD Standard deviation, P25/P75 25th/75th percentile
  2. ascore 0–30, high score indicates healthier nutrition